Published in Obesity and Diabetes Week, May 1st, 2006
Scientists in Canada recently conducted a study to address the "association of hyperprolactinemia with insulin resistance, we hypothesized that patients with hyperprolactinemia may present increased cardiovascular risk markers."
O. Serri and colleagues at the University of Montreal conducted a descriptive clinical trial. They explained, "Serum glucose, insulin, insulin resistance, lipids, high sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, tumor necrosis factor (TNF)-alpha and soluble E-selectin (sELAM-1)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.